These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24788656)

  • 1. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
    van Hal SJ; Chen SC; Sorrell TC; Ellis DH; Slavin M; Marriott DM
    J Antimicrob Chemother; 2014 Aug; 69(8):2210-4. PubMed ID: 24788656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.
    Fernández-Ruiz M; Guinea J; Lora-Pablos D; Zaragoza Ó; Puig-Asensio M; Almirante B; Cuenca-Estrella M; Aguado JM; ;
    Clin Microbiol Infect; 2017 Sep; 23(9):672.e1-672.e11. PubMed ID: 28143788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.
    Brosh-Nissimov T; Ben-Ami R
    Clin Microbiol Infect; 2015 Nov; 21(11):1011-7. PubMed ID: 26183300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibility to fluconazole of clinical interest yeasts: new breakpoints].
    García-Agudo L; García-Martos P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):266-8. PubMed ID: 23303258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes.
    Grim SA; Berger K; Teng C; Gupta S; Layden JE; Janda WM; Clark NM
    J Antimicrob Chemother; 2012 Mar; 67(3):707-14. PubMed ID: 22184469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
    Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints.
    Gamaletsou MN; Daikos GL; Walsh TJ; Perlin DS; Ortigosa CJ; Psaroulaki A; Pagoni M; Argyropoulou A; Nepka M; Perivolioti E; Kotsopoulou M; Perloretzou S; Marangos M; Kofteridis D; Grammatikou M; Goukos D; Petrikkos G; Sipsas NV
    Int J Antimicrob Agents; 2014 Sep; 44(3):248-55. PubMed ID: 25108876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
    Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
    J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal resistance in patients with Candidaemia: a retrospective cohort study.
    Aldardeer NF; Albar H; Al-Attas M; Eldali A; Qutub M; Hassanien A; Alraddadi B
    BMC Infect Dis; 2020 Jan; 20(1):55. PubMed ID: 31952505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain.
    Puig-Asensio M; Ruiz-Camps I; Fernández-Ruiz M; Aguado JM; Muñoz P; Valerio M; Delgado-Iribarren A; Merino P; Bereciartua E; Fortún J; Cuenca-Estrella M; Almirante B; ; ;
    Clin Microbiol Infect; 2015 May; 21(5):491.e1-10. PubMed ID: 25703212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and management of candidaemia--a retrospective, multicentre study in five hospitals in the UK.
    Chalmers C; Gaur S; Chew J; Wright T; Kumar A; Mathur S; Wan WY; Gould IM; Leanord A; Bal AM
    Mycoses; 2011 Nov; 54(6):e795-800. PubMed ID: 21615542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study.
    Ghanem-Zoubi N; Zorbavel D; Khoury J; Geffen Y; Qasum M; Predescu S; Paul M
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2397-2404. PubMed ID: 30284179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial epidemiology of candidaemia in neonatal and paediatric intensive care units at the Children's Medical Center, Tehran.
    Charsizadeh A; Mirhendi H; Nikmanesh B; Eshaghi H; Makimura K
    Mycoses; 2018 Jan; 61(1):22-29. PubMed ID: 28872714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
    Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative assessment of Sensititre YeastOne and Micronaut-AM EUCAST for antifungal susceptibility testing in candidaemia isolates.
    Bélik F; Deckers C; Khourssaji M; Huang TD; Denis O; Montesinos I
    J Mycol Med; 2024 Mar; 34(1):101465. PubMed ID: 38401236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals.
    Colombo AL; Garnica M; Aranha Camargo LF; Da Cunha CA; Bandeira AC; Borghi D; Campos T; Senna AL; Valias Didier ME; Dias VC; Nucci M
    Med Mycol; 2013 Jan; 51(1):38-44. PubMed ID: 22762208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility testing and candidaemia at a tertiary referral hospital.
    O'Connell K; Lyons M; Hanahoe B; Cormican M
    Ir Med J; 2011 Feb; 104(2):55-6. PubMed ID: 21465880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.